PT1411938E - Utilizacao da ciclopamina para a preparacao de um medicamento para o tratamento de psoriase - Google Patents

Utilizacao da ciclopamina para a preparacao de um medicamento para o tratamento de psoriase

Info

Publication number
PT1411938E
PT1411938E PT02736467T PT02736467T PT1411938E PT 1411938 E PT1411938 E PT 1411938E PT 02736467 T PT02736467 T PT 02736467T PT 02736467 T PT02736467 T PT 02736467T PT 1411938 E PT1411938 E PT 1411938E
Authority
PT
Portugal
Prior art keywords
cyclopamine
treatment
psoriasis
medication
preparation
Prior art date
Application number
PT02736467T
Other languages
English (en)
Portuguese (pt)
Inventor
Sinan Tas
Oktay Avci
Original Assignee
Sinan Tas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21619326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1411938(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sinan Tas filed Critical Sinan Tas
Publication of PT1411938E publication Critical patent/PT1411938E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
PT02736467T 2001-07-02 2002-04-19 Utilizacao da ciclopamina para a preparacao de um medicamento para o tratamento de psoriase PT1411938E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2001/000027 WO2002078703A1 (en) 2001-07-02 2001-07-02 Use of cyclopamine in the treatment of basal cell carcinoma and other tumors

Publications (1)

Publication Number Publication Date
PT1411938E true PT1411938E (pt) 2005-11-30

Family

ID=21619326

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02736467T PT1411938E (pt) 2001-07-02 2002-04-19 Utilizacao da ciclopamina para a preparacao de um medicamento para o tratamento de psoriase

Country Status (14)

Country Link
EP (4) EP1561464A3 (enExample)
JP (3) JP2004536045A (enExample)
KR (1) KR20090125833A (enExample)
CN (2) CN1525859B (enExample)
AT (2) ATE305300T1 (enExample)
AU (1) AU2001272892B8 (enExample)
BR (1) BR0117063A (enExample)
CA (1) CA2452151C (enExample)
DE (2) DE60113733T2 (enExample)
DK (2) DK1401438T3 (enExample)
ES (3) ES2250434T3 (enExample)
PT (1) PT1411938E (enExample)
RU (1) RU2312661C2 (enExample)
WO (2) WO2002078703A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
CA2452152A1 (en) 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis
US20170326118A1 (en) 2001-07-02 2017-11-16 Sinan Tas Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells
EP1561464A3 (en) * 2001-07-02 2007-04-25 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
EP2404602A1 (en) 2005-08-22 2012-01-11 The Johns Hopkins University Hedgehog pathway antagonists to treat cancer
ES2618785T3 (es) 2005-10-31 2017-06-22 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para tratar el cáncer basados en receptores FZD humanos
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CN103435694A (zh) * 2006-10-31 2013-12-11 美国政府卫生与公共服务部 Smoothened多肽及使用方法
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
EP2129677B1 (en) 2007-03-07 2014-12-17 Infinity Discovery, Inc. Heterocyclic cyclopamine analogs and methods of use thereof
NZ579356A (en) 2007-03-07 2012-04-27 Infinity Pharmaceuticals Inc Cyclopamine lactam analogs and methods of use thereof
JP5639895B2 (ja) 2007-12-27 2014-12-10 インフィニティ ファーマスーティカルズ、インク． 立体選択的還元方法
CN101990542A (zh) * 2008-02-08 2011-03-23 德克萨斯大学董事会 环巴胺酒石酸盐及其用途
CA2738485A1 (en) 2008-09-26 2010-04-01 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US20110275576A1 (en) * 2009-01-06 2011-11-10 Utah State University Carbohydrate-Cyclopamine Conjugates as Anticancer Agents
JP2009143963A (ja) * 2009-03-25 2009-07-02 Sinan Tas 腫瘍細胞のアポトーシスを阻害するためにヘッジホッグ／スムーズンド信号を使用する腫瘍を治療するための製薬組成物
JP6141015B2 (ja) 2009-08-05 2017-06-07 インフィニティ ファーマスーティカルズ、インク． シクロパミン類似体の酵素によるアミノ基転移
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
CA2887711A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
WO2015096654A1 (zh) * 2013-12-26 2015-07-02 中国科学院上海生命科学研究院 Shh信号通路特异性抑制剂的应用
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
WO2017139497A1 (en) * 2016-02-11 2017-08-17 PellePharm, Inc. Hedgehog inhibitor for use in relief of and treatment of pruritus or itching
CA3227688A1 (en) 2021-09-13 2023-03-02 Sinan Tas Effective interventions with aging and diseases of aging of human and their consequences
CN114292279B (zh) * 2022-01-07 2023-05-09 吉林省农业科学院 一种藜芦抗癌有效成分环杷明提取与分离方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851993A (en) * 1994-06-13 1998-12-22 Biotie Therapies Ltd. Suppression of tumor cell growth by syndecan-1 ectodomain
JP5067986B2 (ja) * 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
WO2000016772A1 (en) * 1998-09-23 2000-03-30 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
GB0013674D0 (en) * 1999-06-08 2000-07-26 Lorantis Ltd Therapeutic use
WO2001027135A2 (en) * 1999-10-13 2001-04-19 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
CA2392958A1 (en) * 1999-11-30 2001-06-07 Curis, Inc. Methods and compositions for regulating lymphocyte activity
CU23175A1 (es) * 2000-07-17 2006-09-22 Ct De Investigacion Y Desarrol Formulacion liposomica de propionato de clobetasol
EP1561464A3 (en) * 2001-07-02 2007-04-25 Sinan Tas Use of cyclopamine in the treatment of basal cell carcinoma and other tumors
CA2452152A1 (en) * 2001-07-02 2002-10-10 Sinan Tas Use of cyclopamine in the treatment of psoriasis

Also Published As

Publication number Publication date
CN1525859A (zh) 2004-09-01
WO2002078704A1 (en) 2002-10-10
RU2312661C2 (ru) 2007-12-20
JP5424923B2 (ja) 2014-02-26
ES2246011T3 (es) 2006-02-01
ES2534400T3 (es) 2015-04-22
CN1230169C (zh) 2005-12-07
CA2452151C (en) 2012-01-03
CN1525859B (zh) 2010-05-05
EP1401438B1 (en) 2005-09-28
WO2002078703A8 (en) 2003-06-12
AU2001272892B8 (en) 2006-05-04
RU2004103074A (ru) 2005-05-10
DE60113733T2 (de) 2006-06-29
BR0117063A (pt) 2004-07-27
EP1561464A3 (en) 2007-04-25
DE60204966D1 (de) 2005-08-11
JP2010132691A (ja) 2010-06-17
EP2216022B1 (en) 2015-01-07
DE60204966T2 (de) 2006-05-18
DK1411938T3 (da) 2005-11-07
JP2004536045A (ja) 2004-12-02
EP2216022A1 (en) 2010-08-11
CA2452151A1 (en) 2002-10-10
JP2014028834A (ja) 2014-02-13
KR20090125833A (ko) 2009-12-07
EP2862570A1 (en) 2015-04-22
AU2001272892B2 (en) 2006-03-16
CN1522146A (zh) 2004-08-18
ES2250434T3 (es) 2006-04-16
DK1401438T3 (da) 2006-02-13
DE60113733D1 (de) 2006-02-09
ATE305300T1 (de) 2005-10-15
ATE299022T1 (de) 2005-07-15
WO2002078703A1 (en) 2002-10-10
EP1561464A2 (en) 2005-08-10
EP1401438A1 (en) 2004-03-31

Similar Documents

Publication Publication Date Title
PT1411938E (pt) Utilizacao da ciclopamina para a preparacao de um medicamento para o tratamento de psoriase
PT1202722E (pt) Usos para o tratamento ou prevencao de disturbios do sono usando doses muito baixas de ciclobenzaprina
ATE309798T1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
NZ544472A (en) Compounds and therapeutical use thereof
PT1155692E (pt) Utilizacao de paclitaxel estabilizado com albumina para a preparacao de um farmaco para o tratamento de tumores solidos e o farmaco assim obtido
ES2267706T3 (es) Agentes como la nicotinamida o cardr para el tratamiento de trastornos de la piel.
BR0115162A (pt) Tratamentos antitumorais eficazes
DE60100994D1 (de) Transdermales therapeutisches System für die Erzielung hoher Plasmaspiegel von Rotigotin in der Therapie von Morbus Parkinson
DE60211139D1 (de) Feste arzneizusammensetzung enthaltend 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide und pvp
HUP9802971A1 (hu) Az MMP-inhibitorok alkalmazása a szemben történő érképződés kezelésére
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
PT1102586E (pt) Utilizacao de extractos de ginkgo biloba para a preparacao de um medicamento para o tratamento da esclerose lateral amiotrofica
TR200102512T2 (tr) Tüm ruhsal bozukluklar, adaptasyon bozuklukları ve çeşitli kaygı-depresyon bozukluklarının tedavisinde ya da önlenmesinde yararlı tıbbi ürünlerin hazırlanması için saredutan ve onun farmasötik olarak kabul edilebilir tuzlarının kullanımı.
MXPA04001912A (es) Aminobenzofenonas novedosas.
PT1220676E (pt) Prevencao do cancro colorrectal
BR0210007A (pt) Uso de inibidores de il-18 para tratamento ou prevenção de lesões do sistema nervoso central
EP1330251A4 (en) POLYTHERAPY FOR THE TREATMENT OF OESTROGENIC SENSITIVE DISEASE
IT1320192B1 (it) Composizione terapeutica per la cura della psoriasi.
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
NO20032799D0 (no) Nye terapeutiske anvendelser av tienylsykloheksylamin- derivater
PT1620116E (pt) Utilização da quina para a preparação de um medicamento que estimula a angiogenese
ITTV20020159A1 (it) Medicamento fitoterapico per il trattamento delle piaghe da decubito e delle lesioni cutanee in genere ottenuto dalla combinazione di principi attivi contenuti in alcune piante.
AR019703A1 (es) Composicion neuroprotectora para la prevencion y/o tratamiento de alteraciones nerviosas y del comportamiento debidas a estados de ansiedad o depresion